EVOLUTION OF SPASTICITY IN POST STROKE PATIENTS TREATED WITH CEREBROLYSIN AND BFT

This is an automatically generated default intro template – please do not edit.

	Read full article
Article Title:	EVOLUTION OF SPASTICITY IN POST STROKE PATIENTS TREATED WITH CEREBROLYSIN AND BFT
Authors:	DIANA UIVAROȘAN1, KATALIN FODOR2, LAVINIA PURZA2,3, CIPRIAN IOVAN1*, LAURA ENDRES1, DELIA MIRELA ŢIŢ2
Affiliation:	1Preclinical disciplines Department, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 2Pharmacy Department, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 3 Doctoral School of Biomedical Sciences, University of Oradea, Oradea
Abstract:	The aim of our study was to monitor the evolution of spasticity in patients who have suffered a stroke and were treated with Cerebrolysin and BFT (balneophysiotherapy). The study was conducted over one year period in which patients were evaluated at the beginning of the period, at 6 months and at the final – at 12 months. Patients were divided into 2 groups, as follows: group I – 71 patients (Cerebrolysin was administered to them and they also did medical recovery) and group II – 68 patients (they only undergoing standard medical recovery procedures). The evolution of spasticity through the Ashworth scale shows progress both in the BFT + Cerebrolysin group and in the BFT group as well. Thus, if the BFT + Cerebrolysin group initially recorded a percentage of 43.66%, at the 6-months evaluation it decreased by 11.27%, reaching at the 12-months evaluation to a score of 25.35%. In the case of the BFT group the percentage at the initial assessment was 42.26%, decreasing by 7.04% at the 6 months assessment and another 5.63% at the 12-months assessment.
Keywords:	cerebrovascular accident (CVA), spasticity, Cerebrolysin, BFT, stroke;
References:	Asplung K.et al Prehospital delay after acute stroke in Kaohsiung Taiwan. Stroke, 35; 70-704; 2004. Arene N, Hidler J, Understanding motor impairment in the paretic lower limb after a stroke; a review of the literature. Top stroke rehabilitation, 16(5), 346-356, 2009. Alvarez XA, Lombardi VR, Fernández-Novoa L, García M, Sampedro C, Cagiao A, Cacabelos R, Windisch M , Cerebrolysin reduces microglial activation in vivo and in vitro ; a potential mechanism of neuroprotection. J Neural Transm Suppl., 59, 281-292, 2000. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D and Moessler H, A -24 week double-blind, placebo-controlled study of three dosage of Cerebrolysin in patients with mild and Alzheimer′s disease. European Journal of Neurology, 13, 43-54, 2006. Bonita R, Epidemiology of stroke. The Lancet, 339, 342-344, 1992. Bejenaru O,Tiu C, Moessler F, Muresanu B, Popescu O, Novak P, Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke. Journal of Medicine and Life, 3(2), 137-143, 2010. Fodor K., Tit D. M., Pasca B., Bustea C., Uivarosan D., Endres L., Iovan C., Abdel-Daim M., Bungau S, Long-term resveratrol supplementation as a secondary prophylaxis for stroke, Oxid. Med. Cell. Longev., 2018; 2018: 1-10, ID 4147320. Francisco GE, McGuire JR, Poststroke Spasticity Management. Stroke, 43:3132-3136, 2012. Hong Z, Moessler H, Bornstein N, Brainin M, Heiss WD, CASTA-Investigators, A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia–CASTA. Int J Stroke. 4(5), 406-12, 2009. Langhorne P, Coupar F, Polloch A , Motor recovery after stroke a systematic review. The Lancet Neurology, 8, 741-754, 2009. Lopez AD , Mathers CD , Ezzati M , Jamison DT , Murray CJ, Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet, 367(9524), 1747-57, 2006. Lup CDA Impactul accidentului vascular cerebral- V.Br Med Bull. 6, 256-286, 2000. Muresanu FD.; Factori neurotrofici.Ed. Libripress, Bucuresti, Romania, 2003. Muresanu DF, Neuromodulation with Pleiotropic and Multimodal, Drugs-Future Approaches to Treatment of Neurological Disorders Brain Edema. Acta Neurologica Supplementum, 106, 4-60, 2010. Marcovici H, Zolog A, Accidentul vascular cerebral, Clinica si Terapie p.33, 2004. Pollock A, Baer G, Langhorne P, Pomeroy V, Physiotherapy treatment approaches for the recovery of postural control and lower limb function following stroke: a systematic review. Clin Rehabil, 21(5), 395-410, 2007. Popescu CD, Stimularea neuroprotectiei cerebrale prin mijloace farmacologice si de neuroreabilitare; Clinica de Neurologie – Spitalul clinic de recuperare UMF-GR. T. Popa Iasi 2014. Satkunam LE, Rehabilitation medicine: Management of adult spasticity. CMAJ 2003: 169, 1173-1179, 2003. Van Peppen RP, Kwakkel G, Wood Dauphinee S, Hendriks HJ, Van der Wees PJ, Dekker J, The impact of physical therapy on functional outcomes after stroke: what′s the evidence, Clin Rehabit, 18(8), 833-862, 2004. Uivarosan D, Teza de doctorat, Importanta medicatiei neurotrofice asociata tehnicilor de recuperare moderne la pacientul cu AVC, Universitatea din Oradea, 2014. Uivarosan D, Importanta medicatiei neurotrofice associate tehnicilor modern de recuperare la pacientul cu AVC, Editura Universitatii din Oradea, 2016.
*Correspondence:	Iovan Ciprian, University of Oradea, Faculty of Medicine and Pharmacy, Preclinical disciplines Department, 1 Decembrie, 10, 410028, Oradea, Romania, Tel. +4 0742 963 812, email: dr.iovan@biostandard.ro